ABO 101 - Arbor Biotechnologies
Alternative Names: ABO-101 - Arbor BiotechnologiesLatest Information Update: 19 May 2024
At a glance
- Originator Arbor Biotechnologies
- Class Gene therapies
- Mechanism of Action Gene expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Hyperoxaluria
Most Recent Events
- 09 May 2024 Preclinical trials in Hyperoxaluria in USA (Parenteral)
- 09 May 2024 Pharmacodynamics data from preclinical trial in Hyperoxaluria released by Arbor Biotechnologies
- 09 May 2024 Arbor Biotechnologies plans clinical trial in Hyperoxaluria (Parenteral)